Duke University Health System

Running trials

• Not yet recruiting

  Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

  NCT07493577· Phase 1/2· Dr David Hasan, M.D.· Source

• Not yet recruiting

  Visual Restoration Using Focused Ultrasound Stimulation and Immersive Virtual Reality After Stroke

  NCT06875206· Duke University· Source

• Not yet recruiting

  Lung Cancer and Aging: Improving Well-being for Older Adults With Lung Cancer

  NCT06636721· Duke University· Source

• Not yet recruiting

  IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency

  NCT07686692· Phase 4· Duke University· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  IL-17 Blockade to Decrease irAEs (REPLAY)

  NCT07237594· Phase 1· Duke University· Source

• Recruiting

  Duke Customized Aortic Aneurysm Repair With Endovascular Stent-grafts - Duke CARES Trial

  NCT07064460· Chandler Long, MD· Source

• Recruiting

  Cardiac point-of Care Ultrasound Training Pathway for Emergency Department Advanced Practice Providers

  NCT07159269· Duke University· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

  NCT06822972· Phase 2· Duke University· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Recruiting

  Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  NCT06333899· Early phase 1· Nationwide Children's Hospital· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Active, not recruiting

  A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

  NCT06872125· Phase 3· Stoke Therapeutics, Inc· Source

• Recruiting

  Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

  NCT06517641· Phase 2· Medical College of Wisconsin· Source

• Recruiting

  Sleep-Sensitive Seizure Risk Assessment With Wearable EEGs

  NCT06545643· Duke University· Source

• Recruiting

  Study of Olutasidenib and Temozolomide in HGG

  NCT06161974· Phase 2· Rigel Pharmaceuticals· Source

• Recruiting

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· Phase 2/3· Bicara Therapeutics· Source

• Enrolling by invitation

  Accelerating TMS for Cervical Dystonia

  NCT06328114· Phase 2· Duke University· Source

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

  NCT06643481· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  NCT05843253· Phase 2· Nationwide Children's Hospital· Source

• Recruiting

  Targeted Pediatric High-Grade Glioma Therapy

  NCT05839379· Nationwide Children's Hospital· Source

• Recruiting

  A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

  NCT06308978· Phase 1· Fate Therapeutics· Source

• Enrolling by invitation

  5-SENSE Score Validation Study

  NCT06138808· Duke University· Source

• Active, not recruiting

  Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer

  NCT05634720· Phase 4· Duke University· Source

• Active, not recruiting

  Accelerated TMS for Focal Hand Dystonia

  NCT06015672· Duke University· Source

• Active, not recruiting

  IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

  NCT05987332· Phase 2/3· IDEAYA Biosciences· Source

• Enrolling by invitation

  Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle

  NCT06002165· University of North Carolina, Chapel Hill· Source

• Recruiting

  Excision of Lymph Node Trial (EXCILYNT) (Mel69)

  NCT05839912· Craig L Slingluff, Jr· Source

• Active, not recruiting

  A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

  NCT05487599· Phase 1/2· Prevail Therapeutics· Source

• Recruiting

  A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

  NCT05489705· Bristol-Myers Squibb· Source

• Active, not recruiting

  Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  NCT05280470· Phase 2· Daiichi Sankyo· Source

• Recruiting

  A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

  NCT04655404· Early phase 1· Nationwide Children's Hospital· Source

• Recruiting

  A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

  NCT04462770· Phase 3· Epygenix· Source

• Recruiting

  Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

  NCT04278404· Duke University· Source

• Active, not recruiting

  IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

  NCT04086264· Phase 1/2· AbbVie· Source

• Active, not recruiting

  A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

  NCT03561220· University of Florida· Source

• Active, not recruiting

  Hepatic Resection for Metastatic Pancreatic Cancer

  NCT02892305· Duke University· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure6 recruiting
• Childhood cancers5 recruiting
• Glioblastoma4 recruiting
• Epilepsy3 recruiting
• High blood pressure2 recruiting
• Melanoma2 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Aortic aneurysm1 recruiting
• Aplastic anaemia1 recruiting
• Asthma1 recruiting
• Brain aneurysm1 recruiting
• Coronary artery disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Down syndrome1 recruiting
• Dystonia1 recruiting
• Haemophilia1 recruiting
• Head and neck cancer1 recruiting
• Huntington's disease1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Insomnia1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Multiple myeloma1 recruiting
• Obesity1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Stroke1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  Black Resilient Caregivers

  NCT06458790· Duke University· Source

• Completed

  The Duke-Reinvestment Partners Community Collaborative (DRC)- Healthy Homes

  NCT05934370· Duke University· Source

• Withdrawn

  Thalamic Stimulation for Epilepsy Study

  NCT04102254· Duke University· Source

• Completed

  A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

  NCT05122650· Phase 2· Jazz Pharmaceuticals· Source

• Completed

  RESILIENCE: Personalizing Cardiovascular Health

  NCT04551872· Duke University· Source

• Completed

  Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

  NCT03070392· Phase 2· Immunocore Ltd· Source

• Withdrawn

  Registry for Pancreatic Cancer

  NCT03001505· Duke University· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Pompe disease6 works · 0 trials